Remed Co

Remed Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Remed Co (302550.KQ) as of Oct 28, 2026 is 3.72. In the previous year, Total Debt to EBITDA Ratio was 4.22 — a change of -11.78% (lower).

Debt/EBITDA

3.72

YoY

-11.78%

Last updated:

Total Debt to EBITDA Ratio of Remed Co is 2025 3.72 . Total Debt to EBITDA Ratio of Remed Co was 2024 4.22 . It decreases by -11.78% lower compared to the previous year.

The Remed Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
10.50 KRW
Jan 1, 2018
-8.77 KRW
Jan 1, 2019
1.29 KRW
Jan 1, 2020
9.81 KRW
Jan 1, 2021
15.14 KRW
Jan 1, 2023
9.80 KRW
Jan 1, 2024
4.22 KRW
Jan 1, 2025
3.72 KRW
The Remed Co Debt/EBITDA history
YEARDebt/EBITDAYoY
3.72-11.78%
4.22-56.95%
9.80-35.31%
15.14+54.38%
9.81+662.81%
1.29-114.67%
-8.77-183.48%
10.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Total Debt to EBITDA Ratio of Remed Co is 3.72 in 2025.

Total Debt to EBITDA Ratio of Remed Co changed from 4.22 to 3.72, representing a -11.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Remed Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Remed Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Remed Co

All Key Metrics — Remed Co